BeOne's Q3: BRUKINSA drives 34% growth and wider margins, but guidance implies a softer Q4

The quarter in numbers

BeOne Medicines reported third-quarter 2026 total revenue of $1,889,815 thousand, up 34% from $1,412,284 thousand a year earlier. Net product revenue was $1,855,057 thousand (+33%), and other revenue roughly doubled to $34,758 thousand (+101%). Nine-month revenue reached $5,108,324 thousand, up 33%.

Profit grew faster than sales. GAAP income from operations was $418,675 thousand against $163,114 thousand a year ago (+157%). Adjusted income from operations rose 79% to $612,226 thousand. GAAP net income was $384,706 thousand (+208%) and adjusted net income $538,735 thousand (+77%). Diluted EPS per ADS was $3.28 on a GAAP basis (from $1.09) and $4.59 on a non-GAAP basis (from $2.65). By our calculation, GAAP operating income was about 22% of revenue, versus about 12% in the prior-year quarter.

What drove growth

BRUKINSA (zanubrutinib) remains the engine. Global sales were $1.4 billion, up 34%, and U.S. sales were $1.0 billion, up 36%. The release does not break out the ex-U.S. figure, and it does not separate price from volume, so the mix of growth cannot be read from this document.

TEVIMBRA (tislelizumab) posted global sales of $243 million, up 28%. Products in-licensed from Amgen reached $167 million, up 26%. Both grew more slowly than BRUKINSA, which the company said lifted gross margin through mix. The company also cited its next-generation BCL2 inhibitor BEQALZI (sonrotoclax) as joining the portfolio, but the release gives no sales figure for it.

Margins, costs and cash

GAAP gross margin on product sales was 88%, up from 86%. The company attributed the gain to a higher proportion of BRUKINSA sales and to productivity improvements that lowered costs for BRUKINSA and TEVIMBRA. A non-cash intangible asset impairment charge of $22 million, tied to the decision to discontinue promoting POBEVCY, partly offset these. Adjusted gross margin, which excludes depreciation and amortization and the impairment, rose to 90% from 86%.

Operating expenses grew more slowly than revenue. GAAP R&D was $660,784 thousand (+26%), which the company linked to moving early clinical programs into late stage and preclinical programs into the clinic. GAAP SG&A was $593,460 thousand (+12%), reflecting investment to support commercial growth. Total GAAP operating expenses were $1,254,244 thousand (+19%), against revenue growth of 34%. On a non-GAAP basis, operating expenses rose 24% to $1,089,887 thousand.

Free cash flow was $473,532 thousand, up $119 million from the prior year, and $1,069,423 thousand for nine months versus $561,916 thousand.

Guidance: raised, with a notable Q4 implication

BeOne lifted full-year 2026 total revenue guidance to $6.9-$7.0 billion from $6.6-$6.8 billion. GAAP operating income guidance rose to $1.2-$1.3 billion from $1.0-$1.1 billion, and non-GAAP operating income to $1.9-$2.0 billion from $1.7-$1.8 billion. GAAP operating expense guidance (combined R&D and SG&A) narrowed to $4.9-$5.0 billion from $4.8-$5.0 billion. Gross margin is still expected in the high-80% range. The company said guidance assumes November 1, 2026 exchange rates and no new, material business development activity.

Subtracting nine-month results from the guidance ranges implies a fourth quarter below the third on several lines. This is our arithmetic, not company commentary. Revenue would be roughly $1.79-$1.89 billion against $1.89 billion in Q3. GAAP operating income would be roughly $206-$306 million against $419 million. GAAP operating expenses would be roughly $1.34-$1.44 billion against $1.25 billion. The release does not explain the shape. It may reflect caution, or heavier year-end investment, but the document does not say.

Below the operating line, the company guided to $25-$50 million of other expense, including interest amortization from the Royalty Pharma arrangement, and about 118 million diluted ADSs. It also said it expects to reverse certain valuation allowances in the fourth quarter of 2026, producing a material tax benefit whose size it is still assessing. That will distort GAAP net income and EPS comparisons.

Pipeline and regulatory catalysts

The nearest catalyst is BRUKINSA's Phase 3 MANGROVE study in first-line mantle cell lymphoma. The FDA granted Priority Review to the filing, and EU and China submissions are complete. Interim results are slated for the Plenary Scientific Session at ASH 2026, where BeOne has 29 BRUKINSA abstracts, plus 10 for BEQALZI and 6 for tacabrutideg. A Japan submission for first-line MCL is planned for Q4 2026.

Tacabrutideg, a BTK degrader, met its primary endpoint of overall response rate in the pivotal Phase 2 portion of CaDAnCe-101 in relapsed/refractory CLL. A potential submission is pencilled for mid-2027, with a Phase 3 combination with BEQALZI to start in 1H 2027.

In solid tumors, the FDA approved a TEVIMBRA-based regimen for first-line HER2+ gastroesophageal adenocarcinoma, and Japan approved TEVIMBRA in first-line nasopharyngeal cancer. China regulatory actions for TEVIMBRA and ZIIHERA in first-line HER2+ GEA are expected in 1H 2027. BGB-B2033 (GPC3x4-1BB) has three hepatocellular carcinoma studies planned for Q4 2026 to 1H 2027. BG-C477 received FDA Fast Track designation. Corporate updates included a collaboration with Revolution Medicines on RAS(ON) inhibitors, with regional rights in select Asian markets, and a voluntary agreement with the U.S. Government tied to U.S. manufacturing.

What to watch

Watch four things: the MANGROVE plenary data and the FDA Priority Review outcome; whether Q4 delivers the step-down the guidance arithmetic implies; the size of the fourth-quarter tax valuation allowance reversal; and any disclosure of BEQALZI sales as the BCL2 franchise builds alongside BRUKINSA.